Durvalumab in the treatment of lung cancer

03/2019

MUDr. Leona Koubková

Pneumologická klinika 2. LF UK a FN v Motole, Praha

SUMMARY

Immunotherapy has already become an integral part of advanced non-small cell lung cancer treatment. The results of a number of studies have shown an improvement in the overall survival time, which is often long-lasting at a very good quality of life for patients. Recent studies have also been conducted at lower stages of non-small cell lung cancer or in post-operative adjuvant mode. The results of studies in advanced small cell lung cancer are also promising, with no progress in treatment for decades. Durvalumab is an anti PD-L1 monoclonal antibody that is approved by the Food and Drug Administration and European Medicines Agency based on the results of the PACIFIC study, for the treatment of patients with non-recurrent non-small cell lung cancer stage III, whose disease did not progress after chemoradiotherapy.

Key words

non-small cell lung cancer, small cell lung cancer, immunotherapy, durvalumab, tremelimumab